Alpha 2.0
Login Register
» Authors » Natsumi Shibata

Natsumi Shibata

Explore the profile of Natsumi Shibata including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 18
Followers 0
Related Specialties
Chemistry
Biochemistry
Infectious Diseases
Top 10 Co-Authors
Isamu Shiina
Takahiro Hoshino
Nozomi Ota
Hisashi Urushihara
Shinya Kimura
Naoki Egashira
Takatsugu Murata
Yutaro Maekawa
Yuki Suzuki
Teruyuki Sato
Published In
BMC Infect Dis
ACS Omega
Eur J Med Chem
Biol Pharm Bull
Vaccine
Affiliations
Soon will be listed here.
Recent Articles
1.
Correction to "First Total Synthesis of Tanzawaic Acid B"
Murata T, Tsutsui H, Yoshida T, Kubota H, Hiraishi S, Natsukawa H, et al.
ACS Omega . 2023 Aug; 8(33):30789. PMID: 37636937
[This corrects the article DOI: 10.1021/acsomega.3c03634.].
2.
First Total Synthesis of Tanzawaic Acid B
Murata T, Tsutsui H, Yoshida T, Kubota H, Hiraishi S, Natsukawa H, et al.
ACS Omega . 2023 Aug; 8(30):27703-27709. PMID: 37546667
The first total synthesis of (+)-tanzawaic acid B, a natural polyketide bearing a pentadienoic ester and octalin moiety, has been accomplished. The synthetic improvement from previous synthetic conditions facilitated our...
3.
Correction to: Influenza vaccination effectiveness for people aged under 65 years in Japan, 2013/ 2014 season: application of a doubly robust method to a large-scale, real-world dataset
Shibata N, Kimura S, Hoshino T, Urushihara H
BMC Infect Dis . 2019 Aug; 19(1):709. PMID: 31405366
After publication of the original article [1], in Table 1, in the second and third column, "Vacnee" and "Non-vacnee" should be replaced with "Vaccinee" and "Non-vaccinee".
4.
Influenza vaccination effectiveness for people aged under 65 years in Japan, 2013/2014 season: application of a doubly robust method to a large-scale, real-world dataset
Shibata N, Kimura S, Hoshino T, Urushihara H
BMC Infect Dis . 2019 Jul; 19(1):586. PMID: 31277580
Background: Influenza vaccination is recognized as a primary public health intervention which prevents the illness of patients and relieves the societal burdens of influenza for medical community as well as...
5.
Novel Ridaifen-B Structure Analog Induces Apoptosis and Autophagy Depending on Pyrrolidine Side Chain
Iwasawa T, Shinomiya T, Ota N, Shibata N, Nakata K, Shiina I, et al.
Biol Pharm Bull . 2019 Mar; 42(3):401-410. PMID: 30828072
Ridaifen (RID)-B is an analog derived from tamoxifen (TAM). TAM has an antitumor effect by acting as an antagonist to estrogen receptor (ER). However, TAM is known to also induces...
6.
Anti-proliferative effect of ridaifen-B on hepatoma cells
Hasegawa G, Akatsuka K, Hiruma K, Suda K, Yokoe Y, Mizusawa A, et al.
Biomed Rep . 2018 Jul; 9(2):175-180. PMID: 30013780
Ridaifens (RIDs), a novel series of tamoxifen derivatives, exhibit a potent growth-inhibitory effect against numerous tumor cells regardless of the expression of estrogen receptors, and are thus promising candidates as...
7.
Effectiveness of influenza vaccination for children in Japan: Four-year observational study using a large-scale claims database
Shibata N, Kimura S, Hoshino T, Takeuchi M, Urushihara H
Vaccine . 2018 Apr; 36(20):2809-2815. PMID: 29661585
Background: To date, few large-scale comparative effectiveness studies of influenza vaccination have been conducted in Japan, since marketing authorization for influenza vaccines in Japan has been granted based only on...
8.
Ridaifen-F conjugated with cell-penetrating peptides inhibits intracellular proteasome activities and induces drug-resistant cell death
Tanaka M, Zhu Y, Shionyu M, Ota N, Shibata N, Watanabe C, et al.
Eur J Med Chem . 2018 Feb; 146:636-650. PMID: 29407987
Ridaifen-F (RID-F) potently inhibits proteolytic activities of the 20S proteasome but poorly inhibits those of the 26S proteasome. Here, we report preparation of several conjugates in which various peptides are...